The Daily Pulse

Health

How GLP-1 Weight-Loss Drugs Became Major Protectors of Heart Health

Reported by Rituparna Sen (Section Editor) · Hindustan Times - Health ·

Unconfirmed — Reported by one source so far

Reported by one source so far

Worth knowing
HealthHow GLP-1 Weight-Loss Drugs Became Major Protectors of Heart Health
Representative image · Pexels

GLP-1 receptor drugs are showing major health benefits for the heart beyond their initial use for diabetes and weight loss. Diabetologist Dr Suman Banerjee notes that nobody expected these drugs to help the cardiovascular system during early trials.

Trial Results

A pooled study of 60,000 patients found a 14 percent drop in major heart events and a 12 percent drop in overall deaths. The strongest results came from semaglutide with a 26 percent drop and efpeglenatide with a 27 percent drop. The SELECT trial showed that semaglutide users who did not have diabetes cut their risk of major heart events by 20 percent over three years.

Health Mechanisms

These benefits do not just come from weight loss taking strain off the heart. GLP-1 receptors are found directly in heart muscle and blood vessels. The drugs help reduce inflammation, improve blood vessel function, stabilize plaque, and reduce blood clotting independently of weight loss.

Context

Medicines originally tested for one common health condition often reveal unexpected benefits for related body systems during large long-term clinical trials. Scientists study these broad effects to find new ways to treat complex chronic illnesses that affect multiple organs at once.

ExplainerWhy this matters

What Happened

GLP-1 receptor agonists, originally created to treat diabetes and later used for weight loss, have shown strong protective effects on the heart and blood vessels in recent clinical trials.

Why It Matters

Heart disease is a leading cause of death globally. Finding that a weight-loss and diabetes drug can directly protect heart muscle, lower blood pressure, and reduce severe heart events provides a powerful new tool for doctors treating high-risk patients.

What Happens Next

Researchers continue to run head-to-head trials and long-term studies to see how different GLP-1 drugs compare in protecting various patient groups, especially those with heart failure.

Read more at Hindustan Times - Health →